XML 73 R35.htm IDEA: XBRL DOCUMENT v3.19.3
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)
9 Months Ended
Sep. 30, 2019
Concentration Risk And Geographic Information [Abstract]  
Schedule of Total Revenues from External Customers and Collaborative Partners by Geographic Region
The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme. Although Sanofi Genzyme (Genzyme) sells Aldurazyme worldwide, the revenues earned by the Company are included in the U.S. region, as the transactions are with Genzyme whose headquarters is located in the U.S. Genzyme is the Company’s sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Total revenues by geographic region:
 
 
 
 
 
 
 
United States
$
201,874

 
$
174,722

 
$
562,217

 
$
528,082

Europe
125,485

 
111,069

 
369,585

 
323,940

Latin America
83,799

 
75,400

 
164,132

 
151,955

Rest of world
49,939

 
30,515

 
153,671

 
134,021

Total revenues
$
461,097

 
$
391,706

 
$
1,249,605

 
$
1,137,998


Schedule of Net Product Revenues by Product
The following table disaggregates Net Product Revenues by product. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Net product revenues by product:
 
 
 
 
 
 
 
Aldurazyme
$
22,852

 
$
27,593

 
$
73,945

 
$
117,652

Brineura
19,840

 
9,936

 
46,815

 
27,743

Firdapse
5,668

 
4,977

 
16,262

 
15,080

Kuvan
120,524

 
113,254

 
340,771

 
321,414

Naglazyme
94,408

 
103,089

 
279,462

 
269,171

Palynziq
24,142

 
4,129

 
55,250

 
4,129

Vimizim
163,466

 
123,342

 
411,953

 
368,016

Total net product revenues
$
450,900

 
$
386,320

 
$
1,224,458

 
$
1,123,205


Schedule of Total Net Product Revenues Based on Patient Location
The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme, the Company’s sole customer for Aldurazyme. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
United States
$
175,127

 
$
146,742

 
$
480,330

 
$
409,294

Europe
121,363

 
107,851

 
358,041

 
315,270

Latin America
83,799

 
75,400

 
164,132

 
151,955

Rest of world
47,759

 
28,734

 
148,010

 
129,034

Total net product revenues marketed by the Company
428,048

 
358,727

 
1,150,513

 
1,005,553

Aldurazyme net product revenues marketed by Genzyme
22,852

 
27,593

 
73,945

 
117,652

Total net product revenues
$
450,900

 
$
386,320

 
$
1,224,458

 
$
1,123,205

Schedule of Net Product Revenue Concentrations Attributed to Largest Customers
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Customer A
16
%
 
16
%
 
17
%
 
17
%
Customer B
13
%
 
12
%
 
12
%
 
12
%
Customer C
10
%
 
10
%
 
11
%
 
10
%
Customer D
5
%
 
7
%
 
6
%
 
11
%
Customer E
12
%
 
%
 
6
%
 
%
Customer F
%
 
13
%
 
%
 
6
%
Total
56
%
 
58
%
 
52
%
 
56
%